Incannex engages eurofins to manufacture novel addiction treatments cannquit-n and cannquit-o

Melbourne, australia, nov. 28, 2022 (globe newswire) -- incannex healthcare limited (nasdaq: ixhl) (asx: ihl), (‘incannex' or the ‘company') a clinical-stage pharmaceutical company developing medicinal cannabinoid and psychedelic therapies for unmet medical needs, is delighted to announce that it has engaged multinational contract development and manufacturing organisation (cdmo) eurofins scientific (‘eurofins') to manufacture incannex's two distinct medicated chewable products designed to treat nicotine and opioid addiction disorders.
IXHL Ratings Summary
Quant
IXHL Quant Ranking
Sector
Industry
Quant Rating
Quant Score